# Hormonal Effects of the Oral Gonadotropin Releasing Hormone (GnRH) Antagonist at Different Periods of the Menstrual Cycle

> **NCT04060992** · PHASE4 · UNKNOWN · sponsor: **University of Southern California** · enrollment: 12 (estimated)

## Conditions studied

- Ovulation; Failure or Lack of

## Interventions

- **DRUG:** Elagolix 200 MG Oral Tablet [Orilissa]

## Key facts

- **NCT ID:** NCT04060992
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-01
- **Primary completion:** 2020-10-30
- **Final completion:** 2021-07-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2019-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04060992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04060992, "Hormonal Effects of the Oral Gonadotropin Releasing Hormone (GnRH) Antagonist at Different Periods of the Menstrual Cycle". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04060992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*